Core Laboratories Inc.
CLB
$11.86
$0.252.15%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -36.97% | 30.04% | 180.50% | 46.43% | -76.25% |
| Total Depreciation and Amortization | -0.33% | -2.49% | -1.90% | -0.80% | -1.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 89.78% | 69.64% | -155.58% | 63.21% | 5,429.17% |
| Change in Net Operating Assets | 1,159.23% | -110.18% | 190.91% | -219.94% | 161.95% |
| Cash from Operations | 57.40% | -23.61% | 210.05% | -71.54% | 9,264.62% |
| Capital Expenditure | -60.53% | 4.78% | 6.09% | -11.55% | 20.95% |
| Sale of Property, Plant, and Equipment | 503.01% | -36.06% | -64.92% | 812.31% | -2.99% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -99.05% | 6.80% | 145.76% | 256.44% | 3,650.00% |
| Cash from Investing | -624.85% | 28.53% | 58.54% | 32.26% | 27.80% |
| Total Debt Issued | -62.50% | 100.00% | -42.86% | 16.67% | -84.81% |
| Total Debt Repaid | 16.67% | -14.29% | -23.53% | 37.04% | 67.47% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -2,402.04% | -20.99% | -268.18% | 97.53% | -718.35% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.00% | 0.21% | -0.43% | -0.21% | 0.00% |
| Other Financing Activities | 100.00% | -260.00% | 92.08% | 53.75% | 5.76% |
| Cash from Financing | -119.47% | 35.46% | -235.22% | 77.92% | -208.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -161.31% | 35.84% | 1,443.96% | 86.16% | 84.40% |